Alumis Inc.
ALMS
Rank in Stocks
#9445
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Share Price
$6.55
Last synced: 2026-11-09
Market Cap
$847.80M
Change (1 day)
8.62%
Change (1 year)
23.58%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Alumis Inc. (ALMS)
Category
Healthcare
EPS for Alumis Inc. (ALMS)
EPS as of June 2026 TTM: $-3.80
According to Alumis Inc.'s latest financial reports, its current EPS (TTM) is $-3.80. At the end of 2025 the company had an EPS of $-2.32, an increase over its 2024 EPS of $-10.38.
EPS history for Alumis Inc. from 2022 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.80 | 63.79% |
| 2025 | $-2.32 | -77.65% |
| 2024 | $-10.38 | 247.16% |
| 2023 | $-2.99 | -79.97% |
| 2022 | $-14.93 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -512.11% |
US
|
|
| $-7.07 | 86.05% |
US
|
|
| $-5.29 | 39.21% |
AU
|
|
| $12.88 | -438.95% |
BE
|
|
| $21.56 | -667.37% |
NL
|
Questions about Alumis Inc.'s earnings per share (EPS)
What is Alumis Inc.'s earnings per share (EPS)?
Alumis Inc.'s earnings per share (EPS) over the last twelve months is $-3.80, as of Jun 2026.
What was Alumis Inc.'s earnings per share (EPS) in 2025?
In 2025, Alumis Inc.'s earnings per share (EPS) was $-2.32, compared with $-10.38 in 2024.
How has Alumis Inc.'s earnings per share (EPS) changed since 2022?
From 2022 to 2025, Alumis Inc.'s earnings per share (EPS) was highest in 2025 ($-2.32) and lowest in 2022 ($-14.93).
How does Alumis Inc.'s earnings per share (EPS) compare with similar companies?
Alumis Inc.'s earnings per share (EPS) ($-3.80) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.